Antipsychotic long-acting injections: Prescribing practice in the UK

British Journal of Psychiatry

Volumn 195, Issue SUPPL. 52, 2009, Pages

  Barnes, Thomas R E ^a   Shingleton Smith, Amber ^b   Paton, Carol ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPENTIXOL DECANOATE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

AGE; DRUG EFFICACY; DRUG TOLERABILITY; GENDER; HUMAN; INJECTION; INJECTION SITE REACTION; MEDICAL AUDIT; MONOTHERAPY; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT RESPONSE; UNITED KINGDOM; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; FEMALE; MALE; MIDDLE AGED; STATISTICS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; FEMALE; GREAT BRITAIN; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; SCHIZOPHRENIA;

EID: 71249111470     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.195.52.s37     Document Type: Review

References (37)

1. Barnes TRE, Curson DA. Long-acting depot antipsychotics: a risk-benefit assessment. Drug Saf 1994; 10: 464-479
2. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299 (Pubitemid 32996037)
3. Schooler NR. Relapse and rehospitalisation: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64 (suppl 16): 14-17
4. Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis JPA, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalization due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 224. (Pubitemid 44406713)
5. Zhu B, Ascher-Svanum H, Shi LB, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008; 59: 315-317
6. Svedberg B, Backenroth-Ohsako G, Lützén K. On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003; 12: 110-118
7. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998; 8: 55-66.
8. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001; 62: 855-859 (Pubitemid 33131171)
9. Hay J. Complications at site of injection of depot neuroleptics. BMJ 1995; 311: 421.
10. Jones JC, Day JC, Taylor JR, Thomas CS. Investigation of depot neuroleptic injection site reactions. Psychiatr Bull 1998; 22: 605-607 (Pubitemid 28454778)
11. Barnes TRE. why indeed? Invited commentary on: Why aren't depot antipsychotics prescribed more often and what can be done about it? Advan Psychiatr Treat 2005; 11: 211-213
12. Ziguras S, Lambert TJR, McKenzie DP, Pennella J. The influence of client's ethnicity on psychotropic medication management in community mental health services. Aust N Z J Psychiatry 1999; 33: 882-888 (Pubitemid 30015855)
13. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68; 1751-1762
14. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am J Psychiatry 2004; 161 (suppl): 1-56.
15. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update). National Clinical Practice Guideline 82. NICE, 2009 (http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf).
16. Roberts G, Dorkins E, Wooldridge J, Hewis E. Detained - what's my choice? Part 1: Discussion. Advan Psychiatr Treat 2008; 14: 172-180
17. Dencker S, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6: 367-381
18. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28: 17-29.
19. Humberstone V, wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Aust N Z J Psychiatry 2004; 38: 240-245 (Pubitemid 38578580)
20. Foster K, Meltzer H, Gill B. Adults with a psychotic disorder living in the community. OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 8. TSO (The Stationery Office), 1996.
21. Paton C, Lelliott P, Harrington M, Okocha C, Sensky T, Duffett R. Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients. J Psychopharmacol 2003; 17: 223-229 (Pubitemid 36753540)
22. Hanssens L, De Hert M, Wampers M, Reginster JY, Peuskens J. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemiol Ment Health 2006; 2: 11. (Pubitemid 43960329)
23. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry 2000; 34: 221-236 (Pubitemid 30206762)
24. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS. Clinical and social determinants of use of depot antipsychotics for patients with schizophrenia in Hong Kong. Hong Kong J Psychiatry 2006; 16: 71-75
25. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998; 24: 11-20.
26. West JC, Marcus SC, Wilk J, Countis LM, Regier DA, Olfson M. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008; 34: 995-1001.
27. Paton C, Barnes TRE, Cavanagh MR, Taylor D, Lelliott P, POMH-UK Project Team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192: 435-439 (Pubitemid 351809896)
28. Barnes TRE, Paton c, Cavanagh MR, Hancock E, Taylor DM, UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007; 33: 1397-1401
29. Barnes TRE, Paton C, Hancock E, Cavanagh MR, Taylor D, Lelliott P, et al. Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand 2008; 118: 26-33. (Pubitemid 351832021)
30. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disroders. Clinical Description and Diagnostic Guidelines. WHO, 1992.
31. Priebe S, Fakhoury W, Watts J, Bebbington P, Burns T, Johnson S, et al. Assertive outreach teams in London: patient characteristics and outcomes. Pan-London Assertive Outreach Study, Part 3. Br J Psychiatry 2003; 183: 148-154 (Pubitemid 36963140)
32. Anderson J. The interface with forensic services. In Psychiatric Intensive Care (2nd edn) (eds MD Beer, S Pereira, C Paton): 191-201. Cambridge University Press, 2008.
33. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007; 58: 482-488 (Pubitemid 46640638)
34. Herriot P, Kheirani K. Survey of depot antipsychotic prescribing in southern Adelaide. Australas Psychiatry 2005; 13: 253-257 (Pubitemid 41800921)
35. Bains JJS, Nielssen OB. Combined depot antipsychotic medications with novel antipsychotics in forensic patients: a practice in search of a principle. Psychiatr Bull 2003; 27: 14-16
36. Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication. (Council Report CR138). Royal College of Psychiatrists, 2006.
37. Mahadun PN, Marshall M. Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics. Psychiatr Bull 2008; 32: 53-56 (Pubitemid 351278706)